Clinical trial registry changes: December 2025

Among the trials TrialRedline tracks, 76 changed their ClinicalTrials.gov record in December 2025: 4 status changes to terminated, withdrawn or suspended, 12 primary outcome text edits, 16 completion dates moved later, 23 enrollment changes, 36 other status changes. Each entry shows the previous and updated value and links to the registry's own version comparison.

76Trials with a recorded change
79Registry updates
66Sponsors

Trials terminated, withdrawn or suspended

4 in December 2025. Recruitment status changed to Terminated, Withdrawn or Suspended. Terminated first, then newest.

Primary outcome text edits

12 in December 2025. The text of the main study measures changed. Edits to capitalization, punctuation or spacing alone are left out. Newest first.

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Absolute change from baseline in Positive and Negative Syndrome Scale- Excited Component (PEC) total score. After: Measure: Absolute Change From Baseline in Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score for the First Episode of Agitation.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Change from baseline in hepatic fat fraction assessed by MRI-PDFF. After: Measure: Percent Change From Baseline To Week 12 In Hepatic Fat Fraction Assessed By Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF).

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Change in Performance on the Expressive Communication Subdomain Raw Score of the Bayley Scales for Infant and Toddler Development-4 (Bayley-4) in Cohort 1. After: Measure: Change in Performance on the Expressive Communication Subdomain Raw Score of the Bayley Scales for Infant and Toddler Development-4 (Bayley-4) Without Caregiver Input in Cohort 1.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Change from Baseline to Week 24 in the ALS Functional Rating Scale-Revised (ALSFRS-R) total score. Measure: Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), treatment-related AEs, AEs by severity, and deaths due to AEs.. After: Measure: Change from Baseline to Week 24 in the ALS Functional Rating Scale-Revised (ALSFRS-R) total score. Measure: Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), treatment-related AEs, AEs by severity, and deaths due to AEs Measure: Incidence of treatment-emergent AEs and SAEs Measure: Incidence of treatment-emergent AEs leading to dose interruptions, dose reductions, and/or discontinuations of study drug.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Changes from baseline to post-treatment in glucose nadir during a standardized MMTT following 2 different dose levels of MBX 1416.. After: Measure: Changes from baseline to post-treatment in glucose nadir during a standardized MMTT following different dose levels of MBX 1416..

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Number of Participants With Adverse Events (AEs). After: Measure: Number of Participants With Treatment-emergent Adverse Events (TEAEs).

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Incidence of adverse events observed during dosing of CK--3773274 in patients with HCM. After: Measure: Incidence of Adverse Events (AEs) Measure: Incidence of Left Ventricular Ejection Fraction (LVEF) < 50% Measure: Incidence of Serious Adverse Events (SAEs).

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Duration of Progression Free Survival per Response Evaluable Criteria in Solid Tumors version 1.1 (RECIST 1.1) Measure: Duration of Overall Survival (OS). After: Measure: Duration of Progression Free Survival (PFS) Per Response Evaluable Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Radiology Committee (BIRC) Measure: Duration of Overall Survival (OS).

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Absence of Anterior Chamber Cells at Visit 6. Measure: Absence of Ocular Pain at Visit 4.. After: Measure: Absence of Anterior Chamber Cells at Visit 6. Measure: Absence of Pain at Visit 4..

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Mean Percentage Change in LDL-C From Baseline To Week 12. After: Measure: Mean Percent Change in LDL-C From Baseline To Week 12.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Main Study and Extension Study - Treatment-Emergent Adverse Events. After: Measure: Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs Measure: Number of Participants With Clinically Significant Changes in Chemistry Parameters Measure: Number of Participants With Clinically Significant Changes in Hematology Parameters Measure: Number of Participants With Clinically Significant Changes in Serum Coagulation Parameters.

Check registry source

Completion dates moved later

16 in December 2025. Primary completion date moved later while its type (estimated or actual) stayed the same. Largest move first.

Enrollment changes

23 in December 2025. The participant count changed. Planned and actual counts are shown as recorded. Newest first.

Other recruitment status changes

36 in December 2025. Any other change of recruitment status, such as recruiting to completed. Newest first.

Showing 25 of 36. Browse all tracked trials to open the rest.

Cite this report

TrialRedline, “Clinical trial registry changes: December 2025”. https://trialredline.com/reports/2025-12

Based on public ClinicalTrials.gov record history. How we collect and check the data